 | This articlemay rely excessively on sourcestoo closely associated with the subject, potentially preventing the article from beingverifiable andneutral. Please helpimprove it by replacing them with more appropriatecitations toreliable, independent sources.(April 2011) (Learn how and when to remove this message) |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C30H25Cl2F3N4OS |
| Molar mass | 617.51 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
TM-38837 is a small moleculeinverse agonist/antagonist of theCB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment ofobesity and metabolic disorders by 7TM Pharma.[1] The company has announcedphase I clinical trials.
TM-38837 is among the first of a new generation ofcannabinoid receptor antagonist designed to avoid thecentral nervous system liabilities of the first generation CB1 receptor antagonists such asrimonabant.[2]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
